These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24240109)

  • 1. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.
    Ferté C; Fernandez M; Hollebecque A; Koscielny S; Levy A; Massard C; Balheda R; Bot B; Gomez-Roca C; Dromain C; Ammari S; Soria JC
    Clin Cancer Res; 2014 Jan; 20(1):246-52. PubMed ID: 24240109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
    Ferté C; Koscielny S; Albiges L; Rocher L; Soria JC; Iacovelli R; Loriot Y; Fizazi K; Escudier B
    Eur Urol; 2014 Apr; 65(4):713-20. PubMed ID: 23993162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
    Champiat S; Dercle L; Ammari S; Massard C; Hollebecque A; Postel-Vinay S; Chaput N; Eggermont A; Marabelle A; Soria JC; Ferté C
    Clin Cancer Res; 2017 Apr; 23(8):1920-1928. PubMed ID: 27827313
    [No Abstract]   [Full Text] [Related]  

  • 4. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
    Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
    Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
    Lamarca A; Crona J; Ronot M; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Franca Bezerra RO; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Schaefer N; Sundin A; Costa F; Pavel M; Dromain C;
    Oncologist; 2019 Nov; 24(11):e1082-e1090. PubMed ID: 30910869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial outcomes in older patients with advanced solid tumours.
    Khan KH; Yap TA; Ring A; Molife LR; Bodla S; Thomas K; Zivi A; Smith A; Judson I; Banerji U; de Bono JS; Kaye SB
    Br J Cancer; 2016 Feb; 114(3):262-8. PubMed ID: 26757260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
    Solis-Hernandez MP; Fernandez Del Valle A; Carmona-Bayonas A; Garcia-Carbonero R; Custodio A; Benavent M; Alonso Gordoa T; Nuñez-Valdovino B; Sanchez Canovas M; Matos I; Alonso V; Lopez C; Viudez A; Izquierdo M; Calvo-Temprano D; Grande E; Capdevila J; Jimenez-Fonseca P
    Br J Cancer; 2019 Oct; 121(7):537-544. PubMed ID: 31477779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
    Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A; Leighl N; Joshua AM; Butler MO; Hogg D; Chappell MA; Soultani L; Chow K; Boujos S; Bedard PL
    Cancer; 2019 Apr; 125(8):1341-1349. PubMed ID: 30768786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
    Dromain C; Pavel ME; Ruszniewski P; Langley A; Massien C; Baudin E; Caplin ME;
    BMC Cancer; 2019 Jan; 19(1):66. PubMed ID: 30642293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
    Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
    Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).
    Sun R; Champiat S; Dercle L; Aspeslagh S; Castanon E; Limkin EJ; Baldini C; Postel-Vinay S; Hollebecque A; Massard C; Ammari S; Deutsch E; Soria JC; Marabelle A; Ferté C
    Eur J Cancer; 2017 Oct; 84():202-211. PubMed ID: 28826073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies.
    Jain RK; Lee JJ; Ng C; Hong D; Gong J; Naing A; Wheler J; Kurzrock R
    J Clin Oncol; 2012 Jul; 30(21):2684-90. PubMed ID: 22689801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.
    Bando H; Rubinstein L; Harris P; Yoshino T; Doi T; Ohtsu A; Welch J; Takebe N
    Gastric Cancer; 2017 May; 20(3):481-488. PubMed ID: 27510411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study.
    Carceller F; Bautista FJ; Jiménez I; Hladun-Álvaro R; Giraud C; Bergamaschi L; Dandapani M; Aerts I; Doz F; Frappaz D; Casanova M; Morland B; Hargrave DR; Marshall LV; Vassal G; Pearson AD; Geoerger B; Moreno L
    Eur J Cancer; 2016 Nov; 67():130-140. PubMed ID: 27662616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.
    Papadatos-Pastos D; Roda D; De Miguel Luken MJ; Petruckevitch A; Jalil A; Capelan M; Michalarea V; Lima J; Diamantis N; Bhosle J; Molife LR; Banerji U; de Bono JS; Popat S; O'Brien MER; Yap TA
    Eur J Cancer; 2017 Apr; 75():56-62. PubMed ID: 28214659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
    Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
    Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials.
    Kumar R; Geuna E; Michalarea V; Guardascione M; Naumann U; Lorente D; Kaye SB; de Bono JS
    Br J Cancer; 2015 Mar; 112(7):1157-65. PubMed ID: 25719834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.
    Garrido-Laguna I; Janku F; Vaklavas C; Falchook GS; Fu S; Hong DS; Naing A; Tsimberidou AM; Wen S; Kurzrock R
    Cancer; 2012 Mar; 118(5):1422-8. PubMed ID: 21823111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
    George A; Kristeleit R; Rafii S; Michie CO; Bowen R; Michalarea V; van Hagen T; Wong M; Rallis G; Molife LR; Lopez J; Banerji U; Banerjee SN; Gore ME; de Bono JS; Kaye SB; Yap TA
    Eur J Cancer; 2017 May; 76():52-59. PubMed ID: 28273485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.